Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome

AUTOR(ES)

Benites, Bruno Deltreggia, Lima, Carolina Silva Costa, Lorand-Metze, Irene, Delamain, Marcia Torresan, Oliveira, Gislaine Borba, Almeida, Daiane de, Souza, Carmino Antonio de, Vassallo, Jose, Pagnano, Katia Borgia Barbosa

FONTE

Clinics

DATA DE PUBLICAÇÃO

2013

RESUMO

OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. RESULTS: A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02). CONCLUSIONS: These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients.

Documentos Relacionados

• Primary myelofibrosis: current therapeutic options
• Myelofibrosis: Pathophysiology and Clinical Management
• Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
• Pathogenesis of idiopathic myelofibrosis: role of growth factors.
• Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone